Compare Stryker Corporation (SYK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Tesla, Inc. — how do they compare? Stryker Corporation trades at $277.34 (market cap $106.24B), while Tesla, Inc. trades at $382.55 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 13.9× Stryker Corporation's market cap, and Stryker Corporation pays a 1.27% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Tesla, Inc. for 88 Days on average.
| SYK | TSLA | |
|---|---|---|
Market Cap | $106.24B | $1.48T |
Volume | 2,982,001 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $388.35 | $489.88 |
52-Week Low | $269.75 | $298.16 |
Typical Hold Time | 21 Days | 88 Days |
Enterprise Value | $117.70B | $1.45T |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Tesla (TSLA) trades at $382.70, up 1.35% today, with a bullish technical signal from moving averages but mixed oscillators. The stock faces high valuation multiples (P/E 347.22, P/S 12.8) amid declining profitability, with net income margin falling to 3.67% in 2025. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, though Q2 2026 earnings missed expectations.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and competitive pressures. The consensus price target of $441.36 suggests upside, but investors must weigh high valuation, margin compression, and volatile cash flows. Key catalysts include robotaxi progress and demand recovery, while risks involve execution delays and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
